Flowonix Medical and Cerebral Therapeutics said today that the fifth patient was successfully treated in its Address trial, which features a micro-infusion device controlling drug delivery to a particular part of the brain in patients with medically refractory epilepsy.
The study is the first of its kind, according to the companies. The Address trial is designed to evaluate intra-cerebroventricular delivery of Valproate in patients with focal seizures with temporal lobe onset, with or without secondary generalization.
Get the full story at our sister site, Drug Delivery Business News.
The post Fifth patient treated in Flowonix, Cerebral Therapeutics epilepsy study appeared first on MassDevice.
from MassDevice http://ift.tt/2xdnIlK
Cap comentari:
Publica un comentari a l'entrada